Natera, TransCode Collaborate to Improve Enrollment for Colorectal Cancer Trial

07:53 AM EDT, 10/13/2026 (MT Newswires) -- Natera (NTRA) and TransCode Therapeutics (RNAZ) said Tuesday they are working together to support enrollment for TransCode's phase 2a trial evaluating TTX-MC138 in patients with colorectal cancer. Financial terms were not disclosed. The companies said the cooperation is intended to more efficiently identify patients who meet the trial's MRD-positive eligibility criteria, streamline site-level identification, and improve the speed and quality of enrollment. Patients will be eligible for enrollment if they have completed curative-intent therapy, and if Natera's Signatera test shows they are positive for molecular residual disease, with no radiographic evidence of disease.